164 results about "Nude mouse" patented technology

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

The invention discloses application of an azetidine compound in preparation of a medicine for preventing and treating triple-negative breast cancer, and belongs to the technical field of biological medicine. By adopting an international common triple-negative breast cancer modeling method, the scheme shows that the compound can effectively inhibit the tumor growth state of nude mouse triple-negative breast cancer, inhibit STAT3 705 site tyrosine phosphorylation and induce tumor cells to generate G2-M phase arrest and apoptosis, and has remarkable prevention and treatment effects on triple-negative breast cancer; the compound is expected to become a novel medicine for treating triple-negative breast cancer.

The invention discloses a tissue engineering integrated trachea regeneration construction method based on a frame structure scaffold and application. A multi-tissue-structure integrated gas pipe is constructed based on a 3D printing bioelastomer frame structure support, and the complex structure and physiological functions of a natural gas pipe are highly simulated. The preparation method comprises the following steps: firstly, by utilizing the characteristic that temperature-sensitive hydrogel Pluronic F-127 becomes semi-solid gel at 37 DEG C and is liquefied at a low temperature of 4 DEG C, and by adopting a strategy that the temperature-sensitive hydrogel is sacrificed after occupying, the patterned distribution of chondrocytes and fibroblasts on a two-dimensional plane is realized; secondly, simulating a three-dimensional tubular trachea structure through a 2D-3D (two-dimensional to three-dimensional) rolling assembly strategy, and realizing the ordered regeneration of C-shaped cartilage ring / O-shaped fiber ring alternate distribution and axial strip-shaped fiber bundle triple structures under the skin of the nude mouse. And finally, successfully extracting the airway mucosa epithelium, separating and amplifying enough airway basal cells in vitro, and loading the airway basal cells to the inner wall of the regenerated trachea by utilizing the photo-crosslinking hydrogel, thereby realizing the function simulation of the airway epithelium and enhancing the physiological functionality.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The present invention relates to the technical field of thyroid cancer drugs, and specifically relates to the application of honeysuckle polysaccharide in the preparation of drugs for treating thyroid cancer. Based on the isolation and purification of honeysuckle polysaccharide with good homogeneity, it is found that it has no toxic effect on normal thyroid follicular cells, but selectively inhibits the proliferation of recurrent and metastatic papillary thyroid cancer cells, and has an inhibitory effect on the xenograft tumors of nude mice inoculated with recurrent and metastatic papillary thyroid cancer cell lines. The honeysuckle polysaccharide of this scheme has good homogeneity, a molecular weight of 23 ± 4 kDa, and is mainly composed of five monosaccharides, mainly connected by α-(1→4)-D-GalpA to form the main chain. While the polysaccharide effectively inhibits the cell viability of IHH-4, it has no toxic effect on normal thyroid cells. This technical scheme can solve the technical problem in the prior art of lacking drugs with small side effects and high specificity for treating recurrent and metastatic papillary thyroid cancer, and has an ideal application prospect.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The application discloses a five-heterocycle compound, a preparation method and application thereof. Specifically disclosed are a compound as shown in formula I, a pharmaceutically acceptable salt or solvate thereof, a composition containing the compound, and a pharmaceutical use of the compound for preparing a drug for treating a disease or disorder related to the mechanism of action of KRAS G12C mutant protein. The five-heterocycle compound in the application has the activity of inhibiting the proliferation of Ba / F3 KRAS-G12C cells, NCI-H358 cells and MIA PaCa-2 cells expressing KRAS G12C mutant protein, and has a good inhibitory effect on the growth of a subcutaneous transplanted tumor of a NCI-H358 nude mouse.

The invention provides an application of an ANGPT2 monoclonal antibody in preparation of a medicine for treating non-small cell lung cancer of a subject subjected to heavy ion treatment. Research results show that the promotion effect of the combined treatment of the nevapsumab and the heavy ion irradiation on ANGPT2 overexpression A549 cell cycle arrest and cell apoptosis rate and the inhibition effect on cell invasion, migration and clone forming ability are obviously better than those of the single treatment of the nevapsumab and the heavy ion irradiation. In a nude mouse transplantation tumor model, the inhibition effect of the combined treatment on the growth of ANGPT2 overexpression A549 cell transplantation tumor is more obvious than that of the single treatment of nevapsumab and heavy ion irradiation, and the negative influence on the physiological state of a host is smaller. A new strategy is provided for clinical treatment of the non-small cell lung cancer, and it is indicated that combined application of heavy ion treatment and ANGPT2 monoclonal antibody is expected to improve the treatment effect, prolong the lifetime of a patient and reduce treatment-related side effects, so that the life quality of the patient is remarkably improved.

A primer pair, method, and use for rapidly identifying newborn nude mice. On the basis that a deletion mutation occurs in the base G at position 337 of a coding region of the Foxn1 gene in nude mice, a primer pair introducing an enzyme digestion site is designed according to sequence characteristics. Using the genome of a mouse to be tested as a template, the Foxn1 gene is amplified according to a PCR-RFLP method. The PCR product is then digested with a SmaI restriction endonuclease, and the digested product is genotyped by agarose gel electrophoresis. In addition, a reaction system that can be combined with lateral flow technology is screened, thereby achieving instant detection of the newborn nude mice. The method has the characteristics of simple operation, short time consumption, low cost, instant detection, etc.

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The invention discloses sargassum fusiforme polysaccharide with a barrier repairing function and a preparation method and application thereof. The molecular weight of the sargassum fusiforme polysaccharide is 39-278 kDa, the total sugar content is 50-55 wt%, and the uronic acid content is 29-35 wt%. The preparation method comprises the following steps: (1) hot water extraction: mixing sargassum fusiforme powder with water, and performing hot water extraction, evaporation concentration, alcohol precipitation and freeze-drying; (2) ultrasonic treatment: mixing with water, and performing ultrasonic degradation; and (3) UV / H2O2 degradation: mixing with a H2O2 solution, carrying out UV degradation, removing H2O2, dialyzing, evaporating and concentrating, and freeze-drying to obtain the product. The sargassum fusiforme polysaccharide prepared by the invention can significantly improve the content and expression of filagarisin (FLG) of nude mice and HaCaT cells after UVB irradiation, reduces the percutaneous moisture loss value (TEWL) in nude mice, has a significant skin barrier repair function, and can be used for development and utilization of functional foods and skin care products.

The invention discloses an application of a disulfide bond isomerase single-domain antibody in preparation of a product for treating and / or preventing leukemia, the disulfide bond isomerase single-domain antibody comprises a variable region, and the variable region comprises CDR1, CDR2 and CDR3; the amino acid sequences of CDR1-CDR3 of the disulfide bond isomerase single-domain antibody are sequentially as shown in SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, and the CDR1-CDR3 are defined according to an IMGT definition scheme. The single-domain antibody provided by the invention can be used for remarkably inhibiting the growth of subcutaneous transplanted tumors of Ba / F3BCR-ABLT315I cells in nude mice, and has an obvious inhibiting effect on drug-resistant chronic granulocytic leukemia.

The present application relates to in situ model modeling method, especially for a kind of non-invasive cervical cancer in situ model modeling method of mouse, including selecting several 8 weeks old BALB / c-nude mouse, all mice are divided into non-invasive group and operation group, the age, weight of two groups of mice are compared, and there is no statistically significant difference;Non-invasive group is widened with the cotton stick of diameter 3mm and wipes dry vagina, the tumor block with luciferase fluorescence is immersed in modified hydrogel, after heating and making modified hydrogel solidification, the tissue glue mixed with hard gypsum in modified hydrogel is dropped on the surface of modified hydrogel and quickly inserted into vagina, when there is obstruction, stop deepening, pause 30s and wait for tissue glue to be completely dry, when tumor block is fixed in cervix, it is modeling completion;Operation group first opens abdominal cavity, and tumor tissue of same size is sutured on cervix.This kind of non-invasive cervical cancer in situ model modeling method of mouse, using non-invasive method to replace operation method to establish non-invasive cervical cancer in situ model, can reduce the pain of mouse, reduce experimental difficulty.

The application discloses application of Rhamnus hemisphaerica in preparation of anti-pancreatic cancer drugs, wherein the Rhamnus hemisphaerica is dry root of Semiliquidam bar cathayensis Chang of Rhamnaceae. Researches show that the Rhamnus hemisphaerica can inhibit proliferation, invasion and migration of pancreatic cancer cells Pan-1, promote apoptosis, has anti-pancreatic cancer activity, can significantly inhibit growth of tumor of a subcutaneous nude mouse xenograft model of pancreatic cancer cells Panc-1, significantly inhibit expression of a tumor proliferation related factor Ki67, and has no obvious toxic side effect on mice. The application firstly discloses that the Rhamnus hemisphaerica has obvious anti-pancreatic cancer activity, can be used for preparation of anti-pancreatic cancer drugs, provides a new efficient and safe drug source for treatment of pancreatic cancer, and provides a basis for further development and utilization of the Rhamnus hemisphaerica.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of pyruvate in the preparation of a drug for enhancing the efficacy of lung cancer chemotherapy. The present invention provides a novel drug for treating lung cancer, namely Compound I obtained by structurally modifying sodium pyruvate. Experimental results show that this compound can significantly inhibit the proliferation of lung cancer cells A549 in mice, and at the same time has an inhibitory effect on the growth of human lung cancer A549 cell xenografts in nude mice, expanding the therapeutic potential of existing drugs and providing new treatment options for lung cancer patients. Its high efficiency in treating lung cancer is of great significance in improving the treatment effect and reducing the burden on patients.

The present invention relates to the field of biomedicine technology, and specifically discloses an anti-tumor antigen BAP31 monoclonal antibody, a Cy5-BAP31 directly labeled monoclonal antibody and its application. The monoclonal antibody includes a heavy chain variable region and a light chain variable region. The nucleotide sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.3. The nucleotide sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID NO.2, and its amino acid sequence is shown in SEQ ID NO.4. The anti-BAP31 monoclonal antibody provided by the present invention can specifically recognize the BAP31 molecule, inhibit the subcutaneous tumor formation ability and in vivo metastasis ability of liver cancer cells, and significantly prolong the survival of tumor-bearing nude mice.

The invention discloses a novel application of total glucosides of paeony in preparation of a medicine for treating triple negative breast cancer. In-vitro and in-vivo experiments prove that the total glucosides of paeony can remarkably inhibit proliferation, migration and invasion of triple negative breast cancer cells (MDA-MB-231 and MDA-MB-468), reverse an epithelial-mesenchymal transition process and induce cell apoptosis by inducing mitochondrial injury, inhibiting oxidative phosphorylation and activating a mitochondrial apoptosis pathway. In an MDA-MB-231 cell xenotransplantation tumor nude mouse model, the total glucosides of paeony can effectively inhibit tumor growth. Therefore, the total glucosides of paeony can be used for preparing the medicine for treating the triple negative breast cancer, and a new treatment choice is provided for clinic.

The application relates to the field of biological medicine, and provides application of ADRM1 gene / protein in preparation of a drug for treating osteosarcoma. The ADRM1 gene / protein is applied to preparation of the drug for treating osteosarcoma, can significantly inhibit proliferation, migration and invasion ability of tumor cells, and thus delays occurrence and development of the osteosarcoma. By shRNA intervention technology, the expression of ADRM1 is knocked down, the mRNA and protein levels of ADRM1 in 143b and U2OS osteosarcoma cell lines are significantly reduced, short-term proliferation activity and long-term clone formation ability are inhibited, and migration and invasion characteristics of the cells are effectively weakened. After 143b osteosarcoma cells with the knocked-down ADRM1 are inoculated into nude mice, the growth of the tumor formed by the cells is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor is down-regulated, indicating that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of the osteosarcoma.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention discloses an application of a circRNA marker in diagnosis and treatment of colorectal cancer, the expression level of a circular RNA gene hsacirc0066801 in samples of patients with colorectal cancer and tumor cells is obviously improved, and the overexpression of the circular RNA hsacirc0066801 can obviously promote the proliferation, migration and invasion of the colorectal cancer cells. Meanwhile, knock-down of the hsacirc0066801 can significantly inhibit proliferation, migration and invasion of colorectal cancer cells, in addition, nude mouse tumor formation experiments prove that the tumor volume is significantly increased after overexpression of the hsacirc0066801, and is reduced after knock-down of the hsacirc0066801. Therefore, the hsacirc0066801 can be used as a potential molecular marker and is used as a target spot for clinical diagnosis and treatment of the colorectal cancer.

The utility model relates to the technical field of cage frame tools, and discloses an IVC self-temperature-control cage frame tool suitable for nude mice, which comprises an IVC cage frame and cage boxes, a plurality of uniformly distributed cage box bins are arranged in the IVC cage frame, and first induction coils and induction coil top plates are arranged at air outlets on one sides of the plurality of cage box bins; the cage box can be inserted into the cage box bin, an induction coil access end is arranged on one side of the cage box, and second induction coils are arranged on the inner walls of the periphery and the inner wall of the bottom of the cage box. Under the condition that an existing fresh air system is not changed, secondary auxiliary heating of the cage is achieved, so that the environment temperature in the cage is effectively improved and controlled through one set of fresh air system, and the application possibility under the basic condition of existing facility hardware is achieved.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

The invention relates to the technical field of biology, in particular to application of free fatty acid C19: 0 in promoting esophageal cancer growth and modeling an animal tumor living body model. Results show that the free fatty acid C19: 0 has the capability of promoting proliferation, migration and invasion of esophageal cancer cells no matter in a human esophageal squamous carcinoma cell line EC109 or KYSE150; the tumor formation capability of esophageal cancer cells in nude mice can be remarkably promoted, and basic data is provided for prevention, treatment and prognosis of esophageal cancer.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The invention discloses a benzacridine-3, 4-dicarboximide derivative as well as a preparation method and application thereof, the structure of the benzacridine-3, 4-dicarboximide derivative is shown as I-A, and n is equal to 1, 2, 3 or 4; the invention also discloses hydrochloride of the benzacridine-3, 4-dicarboximide derivative and a preparation method, all the compounds are subjected to CCK-8 experiments to investigate the cytotoxicity to 14 tumor cells and human normal lung embryo fibroblasts, and the compound 4 with the best activity is used for evaluating the cytotoxicity to SK-OV-3 ovarian cancer cell proliferation and invasion, the cytotoxicity to SK-OV-3 ovarian cancer cells, the cytotoxicity to human normal lung embryo fibroblasts and the cytotoxicity to SK-OV-3 ovarian cancer cells and the cytotoxicity to human normal lung embryo fibroblasts. And influence of migration capability. Subsequently, in-vivo anti-tumor activity of the compound 4 is found in a nude mouse xenotransplantation tumor experiment, and whether the compound has toxicity to mice or not is observed through pathological tissue slices under the administration treatment concentration. The invention has great value in discovery of new anti-tumor small molecule drugs and research and development of clinical drugs thereof.

The invention provides an extraction method of high-performance gamma delta T immune cells and application of the high-performance gamma delta T immune cells in tumors. The method comprises the following steps: firstly, separating mononuclear cells from peripheral blood, carrying out activation induction by using a serum-free culture medium containing zoledronic acid, IL-15 and OKT3, and supplementing a culture medium containing IL-2 according to a specific proportion for multiplication culture from the third day of culture. Through the optimization process, the expression rate of TCR-gamma delta < + > is as high as 96.84%, and gamma delta T cells with high activity are obtained. An in-vivo tumor inhibition experiment shows that the cell has a remarkable growth inhibition effect on liver cancer nude mouse transplanted tumor, the effect is equivalent to that of a positive control drug, and obvious toxic and side effects are not observed. The method is stable in process and clear in component, and a reliable technical basis is provided for clinical transformation of gamma delta T cells in immunotherapy of solid tumors and hematologic tumors.

The invention provides an anti-tumor combined treatment method for improving a radiotherapy curative effect by using nintedanib, and relates to the technical field of tumor treatment. The anti-tumor combined treatment method comprises the following steps: selecting a male mouse or a male nude mouse as an experimental animal, and subcutaneously constructing a tumor-bearing mouse model on the back of the experimental animal; when the tumor volume of the tumor-bearing mice reaches 70-100mm < 3 >, randomly dividing the tumor-bearing mice into four groups, namely a control group, a nintedanib single drug group, a radiotherapy group and a combined group; measuring the subcutaneous tumor volume and weight of the tumor-bearing mouse every three days; drawing a mouse tumor growth curve, a mouse survival curve and a mouse weight change curve according to the measured data; a tumor-bearing mouse is subjected to living body imaging, tumor tissue paraffin embedding, immunohistochemical staining, TUNEL staining and Hamp; and E, carrying out section staining and blood biochemical detection, and carrying out data analysis by utilizing corresponding analysis software, so as to evaluate the anti-tumor effect and safety of the combined treatment. According to the invention, tumor growth can be effectively inhibited.

The invention relates to a drug combination of annona squamosa lactone compounds and sorafenib (SF), which is characterized in that four common human hepatoma cell lines HepG2, HuH7, MHCC97H and HCCLM3 are used as research objects, and the drug combination effect among different components is evaluated by using an MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide) method and Synergy Finder software. The combination of the compound and SF shows an obvious synergistic inhibition effect on the growth of hepatoma carcinoma cells, and meanwhile, the pharmaceutical composition can synergistically reduce the ATP level of the hepatoma carcinoma cells and induce hepatoma carcinoma cell apoptosis. Pharmacodynamic experiments show that the compounds annonacin and SF can synergistically inhibit tumor growth and induce tumor cell apoptosis, and have no obvious toxicity to normal organs of nude mice at a low dosage. In addition, transcriptome analysis predicts that the anti-liver cancer target of the annonacin is possibly related to the SLC33A1 gene. The method can be used for preparing anti-hepatoma drugs and researching related mechanisms. The annona lactone compound disclosed by the invention is derived from annona montana Macf. Which is an annona plant, namely annona montana Macf.